Medicine
Zilxi 1.5% foam
Zilxi 1.5% foam is a prescription medicine containing Minocycline for topical use, marketed by Journey Medical, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not store in the refrigerator. ZILXI must be stored at 2 ºC – 8 ºC (36 ºF –…
Key facts
- Active ingredient (INN)
- Minocycline
- Brand
- Zilxi
- Strength
- 1.5%
- Dosage form
- Foam
- Route
- Topical
- Packs
- 1 can
- Marketing authorisation holder
- Journey Medical
- Manufacturer
- Journey Medical
- Origin register
- US FDA, United States
- Storage
- Do not store in the refrigerator. ZILXI must be stored at 2 ºC – 8 ºC (36 ºF – 46 ºF) until dispensed to the patient. Once dispensed, the patient is to store ZILXI at room temperature below 25 ºC (77 ºF) for 90 days. Handling Allow the can to warm to room temperature before first use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A01AB23 Minocycline
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 October 2022
- Identifiers
- RxCUI 2375333, 2375338DailyMed set ID cbffa96e-2446-43cf-ba5e-38c645302afdNDC 69489-212Application NDA213690
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 can in 1 carton / 30 g in 1 can | 69489-212-30 | Journey Medical | 1 June 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 June 1971 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Minocycline
Clinical summary
Minocycline is a tetracycline-class drug indicated in the treatment of infections due to susceptible isolates of the designated bacteria, among other approved uses. MedsAcross supplies Minocycline for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MinocyclineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Minocin prescribing information (Melinta Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Zilxi 1.5% foam for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.